EUCTR2018-002647-29-SE进行中（未招募）1 期
A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements;
- •2. Male or female patient =18 years of age;
- •3. Cholangiocarcinoma verified as adenocarcinoma by histopathology or cytology with a perihilar or distal stenosis that has been stented or will require stenting, and that is accessible for PCI light treatment;
- •4. Cholangiocarcinoma must be considered inoperable with respect to radical resection (including partial liver resection or liver transplantation);
- •5. At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation;
- •6. If metastatic disease, metastasis must be limited to tissues other than bone or the central nervous system;
- •7. Adequate biliary drainage (at least 50% of the liver volume, or at least 2 sectors), with no evidence of active uncontrolled infection (patients on antibiotics are eligible);
- •8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •9. Estimated life expectancy of at least 12 weeks.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 49
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 137
排除标准
- •1. Previously received any anti-tumour (either local or systemic) treatment for CCA except for previous treatment of up to 2 cycles of gemcitabine/cisplatin;
- •2. Severe visceral disease other than CCA;
- •3. A history of frequently recurring septic biliary events;
- •4. Porphyria or hypersensitivity to porphyrins;
- •5. A second primary cancer, with a disease-free interval of <5 years. A second primary cancer that has been treated with intent to cure may be allowed after consultation with the study Medical Monitor. Adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, in situ carcinoma of the uterine cervix, or prostate cancer that is controlled by hormone therapy (patients may continue hormone therapy while on study) are allowed;
- •6. Unable to undergo contrast-enhanced CT or MRI;
- •7. Currently participating in any other interventional clinical study;
- •8. Planned surgery, endoscopic examination, or dental treatment in the first 30 days after PCI treatment;
- •9. Co-existing ophthalmic disease likely to require slit-lamp examination within the first 90 days after PCI treatment;
- •10. Clinically significant and uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to baseline, congestive heart failure, and arrhythmia requiring therapy, except for extra systoles or minor conduction abnormalities and controlled and well treated chronic atrial fibrillation;
- •11. Known allergy or sensitivity to photosensitisers, (the active substance and/or any of the excipients); or chronic use of other photosensitising therapies (Section 5.5.3); treatment with amiodarone during the last 12 months;
- •12. Known hypersensitivity to or contraindication to the use of gemcitabine (the active substance and/or any of the excipients);
- •13. Known hypersensitivity, or contraindication to the use of cisplatin (the active substance and/or any of the excipients);
- •14. Ataxia telangiectasia;
- •15. Upon the Investigator’s discretion, evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the planned PCI treatment, affect patient compliance or place the patient at high risk from treatment-related complications;
- •16. Plans to have, or has recently had, vaccination with a live vaccine, including for yellow fever;
- •17. Concurrently receiving treatment with phenytoin;
- •18. Male patients unwilling to use highly effective contraception or women of childbearing potential (WOCBP) unwilling to use a highly effective form of contraception such as the following:
- •- Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal and transdermal)
- •- Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable)
- •- Intrauterine devices
- •- Intrauterine hormone-releasing system
- •- Bilateral tubal ligation
- •- Vasectomised partner
- •- Sexual abstinence
- •Patients must continue the use of contraception during PCI treatment and subsequent chemotherapy, and for at least 9 months after last dose of Amphinex or 6 months after last dose of chemotherapy, whichever is the latest.
- •19. Breastfeeding women or women with a positive pregnancy test at baseline;
- •20. Inadequate bone marrow function as evidenced by one of the following:
- •- Absolute neutrophil count (ANC) <1.5 × 109/L
- •- Platelet count <100 × 109
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/gemcitabine treatment complemented by combination chemotherapy, compared to combination chemotherapy alone, in patients with bile duct cancer.Inoperable CholangiocarcinomaMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2018-002647-29-BEPCI Biotech AS186
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/gemcitabine treatment complemented by combination chemotherapy, compared to combination chemotherapy alone, in patients with bile duct cancer.Inoperable CholangiocarcinomaMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2018-002647-29-FIPCI Biotech AS186
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/gemcitabine treatment complemented by combination chemotherapy, compared to combination chemotherapy alone, in patients with bile duct cancer.EUCTR2018-002647-29-DKPCI Biotech AS186
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/gemcitabine treatment complemented by combination chemotherapy, compared to combination chemotherapy alone, in patients with bile duct cancer.Inoperable CholangiocarcinomaMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2018-002647-29-NOPCI Biotech AS186
进行中（未招募）
1 期
A study to investigate the safety, tolerability and efficacy of PCI/gemcitabine treatment complemented by combination chemotherapy, compared to combination chemotherapy alone, in patients with bile duct cancer.Inoperable CholangiocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864EUCTR2018-002647-29-ESPCI Biotech AS186